LONSURF trifluridine and tipiracil

Drug Class

Nucleoside metabolic inhibitor and thymidine phosphorylase inhibitor

Mechanism

Trifluridine interferes with tumor DNA synthesis and cell proliferation, while tipiracil inhibits thymidine phosphorylase to prevent the degradation of trifluridine.

Approved Indication

Previously treated metastatic colorectal cancer, and previously treated metastatic gastric or gastroesophageal junction adenocarcinoma, per its FDA approval.

What This Means For Patients

LONSURF is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2015) — Sources

Pivotal Clinical Evidence

• RECOURSE — Mayer et al., N Engl J Med 2015 (NCT01607957) — Sources

Sources

• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lonsurf-metastatic-colorectal-cancer
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207981s000lbl.pdf